LGVN · Longeveron Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $398.0K | - | $137.0K | $316.0K | $548.0K | - | $773.0K | $468.0K | $548.0K | - |
| Cost of Revenue | $134.0K | - | $12.0K | $170.0K | $106.0K | - | $91.0K | $124.0K | $219.0K | - |
| Gross Profit | $264.0K | - | $125.0K | $146.0K | $275.0K | - | $682.0K | $344.0K | $329.0K | - |
| R&D | $2.32M | - | $3.85M | $2.95M | $2.52M | - | $2.21M | $1.72M | $2.22M | - |
| SG&A | $2.72M | - | $3.58M | $2.59M | $2.94M | - | $3.13M | $2.12M | $2.20M | - |
| Total Operating Expenses | $5.04M | - | $7.43M | $5.54M | $5.46M | - | $5.33M | $3.84M | $4.42M | - |
| D&A | $200.0K | - | $200.0K | $200.0K | $200.0K | - | $200.0K | $200.0K | $200.0K | - |
| Operating Income | ($4.78M) | - | ($7.31M) | ($5.40M) | ($5.18M) | - | ($4.65M) | ($3.50M) | ($4.09M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($4.74M) | - | ($7.22M) | ($5.03M) | ($5.01M) | - | ($4.42M) | ($3.41M) | ($4.06M) | - |
| EPS - Basic | ($0.19) | - | ($0.39) | ($0.33) | ($0.34) | - | ($0.34) | ($1.83) | ($1.61) | - |
| EPS - Diluted | ($0.19) | - | ($0.39) | ($0.33) | ($0.34) | - | ($0.34) | ($1.83) | ($1.61) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.76M | $4.66M | $9.24M | $10.33M | $14.33M | $19.23M | $22.78M | $12.38M | $1.94M | $4.95M |
| Accounts Receivable | $68.0K | $104.0K | $52.0K | $31.0K | $29.0K | $84.0K | $380.0K | $218.0K | $178.0K | $111.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $293.0K | $423.0K | $1.08M | $700.0K | $367.0K | $99.0K | $887.0K | $600.0K | $1.47M | $638.0K |
| Current Assets | $16.86M | $5.45M | $10.34M | $11.27M | $15.28M | $19.62M | $23.77M | $13.41M | $3.76M | $5.85M |
| Total Assets | $21.21M | $10.26M | $15.56M | $16.75M | $20.85M | $25.56M | $29.91M | $19.39M | $9.70M | $12.08M |
| Current Liabilities | $4.34M | $4.09M | $4.94M | $3.28M | $2.72M | $2.58M | $3.10M | $3.21M | $5.29M | $3.89M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $5.18M | $4.59M | $5.59M | $4.09M | $3.69M | $3.67M | $4.28M | $4.48M | $6.66M | $5.34M |
| Stockholders' Equity | $16.03M | $5.67M | $9.97M | $12.66M | $17.16M | $21.89M | $25.63M | $14.91M | $3.04M | $6.74M |
| Retained Earnings | ($137.05M) | ($132.31M) | ($126.87M) | ($119.65M) | ($114.62M) | ($109.61M) | ($105.53M) | ($100.96M) | ($89.04M) | ($84.98M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.37M) | - | - | - | ($4.70M) | - | - | - | ($3.09M) | - |
| Investing Cash Flow | ($20.0K) | - | - | - | ($150.0K) | - | - | - | $14.0K | - |
| Financing Cash Flow | $15.49M | - | - | - | ($58.0K) | - | - | - | $63.0K | - |
| CapEx | $0 | - | - | - | $27.0K | - | - | - | $16.0K | - |
| Free Cash Flow | ($4.37M) | - | - | - | ($4.72M) | - | - | - | ($3.10M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 66.3% | - | 91.2% | 46.2% | 50.2% | - | 88.2% | 73.5% | 60.0% | - |
| Operating margin | -1199.7% | - | -5335.8% | -1707.9% | -945.4% | - | -601.4% | -747.9% | -746.4% | - |
| EBITDA margin | -1149.5% | - | -5189.8% | -1644.6% | -908.9% | - | -575.5% | -705.1% | -709.9% | - |
| Net margin | -1189.9% | - | -5270.8% | -1591.1% | -914.4% | - | -571.7% | -729.3% | -740.5% | - |
| Free cash flow margin | -1098.0% | - | - | - | -862.0% | - | - | - | -566.1% | - |
| FCF / Net income | 0.92 | - | - | - | 0.94 | - | - | - | 0.76 | - |
| R&D / Revenue | 582.7% | - | 2811.7% | 934.8% | 458.9% | - | 285.4% | 367.9% | 404.9% | - |
| SG&A / Revenue | 683.4% | - | 2615.3% | 819.3% | 536.7% | - | 404.3% | 453.4% | 401.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -22.3% | - | -46.4% | -30.0% | -24.0% | - | -14.8% | -17.6% | -41.8% | - |
| Return on equity | -29.6% | - | -72.5% | -39.7% | -29.2% | - | -17.2% | -22.9% | -133.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.88 | 1.33 | 2.09 | 3.43 | 5.61 | 7.60 | 7.67 | 4.18 | 0.71 | 1.50 |
| Quick ratio | 3.88 | 1.33 | 2.09 | 3.43 | 5.61 | 7.60 | 7.67 | 4.18 | 0.71 | 1.50 |
| Cash ratio | 3.63 | 1.14 | 1.87 | 3.15 | 5.26 | 7.45 | 7.35 | 3.86 | 0.37 | 1.27 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.32 | 1.81 | 1.56 | 1.32 | 1.22 | 1.17 | 1.17 | 1.30 | 3.19 | 1.79 |
| Liabilities / Assets | 0.24 | 0.45 | 0.36 | 0.24 | 0.18 | 0.14 | 0.14 | 0.23 | 0.69 | 0.44 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.01 | 0.02 | 0.03 | - | 0.03 | 0.02 | 0.06 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 62d | - | 139d | 36d | 19d | - | 179d | 170d | 119d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 798d | - | 32850d | 1503d | 1264d | - | 3558d | 1766d | 2445d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1608.4x | - | 1382.7x | 1542.1x | 1350.6x | - | 1031.6x | 0.7x | 2.7x | - |
| P / S | 64768.2x | - | 100583.2x | 61762.6x | 42287.7x | - | 34201.7x | 22.4x | 14.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -27.4% | - | -82.3% | -32.5% | 0.0% | - | 191.7% | 0.4% | 96.4% | - |
| Revenue CAGR (3y) | 12.6% | - | -19.7% | -12.1% | 14.0% | - | 49.4% | -1.5% | -31.5% | - |
| Revenue CAGR (5y) | -25.3% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -4.0% | - | -81.7% | -57.6% | -16.4% | - | 1163.0% | 269.9% | 332.9% | - |
| Operating income growth (YoY) | 7.8% | - | -57.2% | -54.2% | -26.7% | - | 9.9% | 38.7% | 13.3% | - |
| Net income growth (YoY) | 5.5% | - | -63.4% | -47.3% | -23.5% | - | 13.5% | 39.4% | 12.7% | - |
| EPS growth (YoY) | 44.1% | - | -14.7% | 82.0% | 78.9% | - | -21.4% | -577.8% | -631.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 7.5% | - | - | - | -52.3% | - | - | - | 47.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -6.6% | -74.1% | -61.1% | -15.1% | 464.2% | 224.7% | 286.4% | 32.4% | -81.4% | -67.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.20M totalReportable Segment Aggregation Before Other Operating Segment$1.20M · 100.0%
Product / service
$1.20M totalClinical Trial Revenue$954.0K · 79.6%
Contract Manufacturing Revenue$222.0K · 18.5%
Contract Manufacturing Lease Revenue$23.0K · 1.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Longeveron Inc. against the 5 most active filers in the same SIC group.